Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

Rockwell Medical is arguably the strongest player in the hemodialysis market and a top 5 healthcare supplier per Seeking Alpha Quant. The Company still addresses a critical medical condition and has a large global market that I don't believe is near fully penetrated. There is an operational turnaround strategy being executed that is focused on cost-cutting and industry roll up to improve financials.

Returning To Rockwell Medical: Buy At 65% Of Revenue

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Heather Hunter - SVP & Chief Corporate Affairs Officer Mark Strobeck - President & CEO Jesse Neri - SVP, Finance Conference Call Participants Anthony Vendetti - Maxim Group LLC Dipesh Patel - H.C. Wainwright Operator Good morning, and welcome to Rockwell Medical's Third Quarter 2023 Results Conference Call and Webcast.

Rockwell Medical, Inc. (RMTI) Q3 2023 Earnings Call Transcript

Rockwell Medical (RMTI) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.40 per share a year ago.

Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended September 30, 2023. "Since we started implementing our new focused business strategy a little over a year ago, we have successfully completed two acquisitions, aligned our cost structu.

Rockwell Medical Announces Third Quarter 2023 Results

Rockwell Medical (RMTI) closed the most recent trading day at $1.95, moving +1.04% from the previous trading session.

Why Rockwell Medical (RMTI) Outpaced the Stock Market Today

The latest trading day saw Rockwell Medical (RMTI) settling at $1.58, representing a -1.25% change from its previous close.

Rockwell Medical (RMTI) Suffers a Larger Drop Than the General Market: Key Insights

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Jesse Neri has 20+ years' experience leading finance functions at both public and private companies.

Rockwell Medical Names Jesse Neri as Senior Vice President, Finance

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Dr. Joan Lau brings 20+ years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private companies.

Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the third quarter ended September 30, 2023 on Tuesday, November 14, 2023.

Rockwell Medical to Release Third Quarter 2023 Results on Tuesday, November 14, 2023

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #ESRD--Rockwell Medical is honored to be entrusted by Centers for Dialysis Care to be its preferred supplier of hemodialysis concentrates.

Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is the preferred supplier of liquid and dry acid and bicarbonate hemodialysis concentrates to Sanderling Renal Services.

Rockwell Medical Enters into 3-Year Product Purchase Agreement with Sanderling Renal Services; Expands Distribution Capabilities Westward into Utah

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical today announced that it entered into an amended and restated products purchase agreement with its largest customer.

Rockwell Medical Enters into Products Purchase Agreement with its Largest Customer, Enhancing Relationship through 2024

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's President and CEO, Dr. Mark Strobeck, will present at H.C. Wainwright's conference on September 12, 2023 at 11:00 am ET.

Rockwell Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Heather Hunter - Senior Vice President and Chief Corporate Affairs Officer Mark Strobeck - President and Chief Executive Officer Paul McGarry - Senior Vice President, Finance and Chief Accounting Officer Conference Call Participants Dipesh Patel - H.C. Wainwright Operator Good morning and welcome to Rockwell Medical's Second Quarter 2023 Results Conference Call and Webcast.

Rockwell Medical, Inc. (RMTI) Q2 2023 Earnings Call Transcript

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #Hemodialysis--Rockwell Medical updated its guidance on profitability and now expects the Company to be profitable in the fourth quarter 2023 and going forward.

Rockwell Medical Announces Second Quarter 2023 Results

Robust product demand and cost-saving initiatives are likely to have boosted Rockwell Medical's (RMTI) second quarter's top line.

Rockwell Medical (RMTI) to Post Q2 Earnings: What's in Store?

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Rockwell Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rockwell Medical stock has seen a massive year-to-date rally, breaking quarterly revenue records and regaining its competitive advantage. The company has significant international expansion potential and is positioned to benefit from positive secular trends in the healthcare industry. The stock is undervalued and presents an attractive opportunity for investors looking to diversify their portfolios with a micro-cap stock.

Rockwell Medical: Upside Potential Outweighs Competition Risk

Owens Corning

Procore Technologies

Earnings season is the best time to make quick gains with any cash you may have to spare.

3 Reasons to Buy PCOR, OC and RMTI

Blade Air Mobility

Dragonfly Energy Holdings Corp

Canoo

Organogenesis Holdings

Rigel Pharmaceuticals

The Metals Co

Interested in discovering the top penny stocks to invest in? You're certainly not the only one.

7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090%

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its financial and operational results for the second quarter ended June 30, 2023 on Monday, August 14, 2023.

Rockwell Medical to Release Second Quarter 2023 Financial Results on Monday, August 14, 2023

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical acquires the hemodialysis concentrates business from Evoqua Water Technologies; Adds fully automated and profitable business.

Rockwell Medical Acquires Hemodialysis Concentrates Business from Evoqua Water Technologies

Rockwell Medical is a micro-cap healthcare company that develops, manufactures, and distributes hemodialysis products worldwide. RMTI's Q1 2023 revenue reached a record high with 22% YoY growth, while gross profit improved and operating expenses significantly decreased. The firm is turning around actively. Once the company's profitability norm is reached, its EV/Sales multiple should be 1.5-2x, which is 167-222% higher than today.

Rockwell Medical: This Top-Rated Stock Has A Lot More To Show

Rockwell Medical (RMTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Rockwell Medical (RMTI) Soars 20.0%: Is Further Upside Left in the Stock?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

News for Rockwell Medical Stock (RMTI)